GeneDx Rewrites the Playbook: From Volume to Value in Genomic Testing
New leadership and a laser focus on revenue cycle management position the company to convert coverage into cash, with the ARR tailwind expected to hit in 2027.
WGS · Earnings Call · 2026-08-03
The New Focus
After years of chasing volume, GeneDx is now chasing payment. In Q2 2026, the company's genome mix shift back toward exome and reflex products, combined with a renewed emphasis on revenue cycle management, became the centerpiece of management's story. Katherine Stueland put it bluntly: “we must be relentless in our efforts to improve the rate at which we get paid for our services. It's the single biggest opportunity for us.” — Katherine Stueland, Chief Executive Officer · 2026-08-03 Mark Gardner, the new President, laid out four operational levers—mix management, payer coverage, payer-specific workflows, and technology. He said: “We are underearning today on both exome and genome testing, and this is a significant opportunity that the whole of our company has rallied around.” — Mark Gardner, President · 2026-08-03 This is a departure from prior quarters' emphasis on "utilization" and "genome volume." The keyword trajectory shows collection rate climbing to #2 in Q2 2026, while "revenue cycle management" appears in the top 20 for the first time. Kevin Feeley quantified the opportunity: outpatient genome collection rate is only 32%, vs. a mature-test industry standard of ~70%. “if we were to double that 32% collection rate, what are zeros in our blended ARR today become paid units, driving revenue uplift that falls directly to the bottom line.” — Kevin Feeley, Chief Financial Officer · 2026-08-03Coverage is Moving, Payment Lags
The single biggest near-term catalyst is Carelon's decision to expand commercial genome coverage from 47% to 87% of lives in one quarter. Yet management warns that coverage leads and payment lags, with most benefits expected in Q4 2026 and 2027. Payer coverage is now a formal pillar of the strategy, but the company is realistic: only 67% of outpatient genome volume is currently submitted to payers with an active positive coverage policy—up from 38% a year ago. This is a continuation of a theme that management has sounded for over a year. In the May 2026 call, Kevin said: “We have run this playbook before; we are just years behind exome in driving commercial payers and Medicaid towards improving coverage similar to exome.” — Kevin Feeley, Chief Financial Officer · 2026-05-04 The difference now is that the playbook is explicitly codified into four levers, and the company has brought in a new president and several revenue-cycle veterans to execute it.Unit Economics Take Center Stage
The financials support the narrative. While total revenue grew 11% YoY to $114.4M, exome/genome volume grew 32%. The divergence is due to the mix shift toward exome and reflex—genome now accounts for 32% of outpatient insurance-based volume, down from 40% in Q1—and the still-low collection rate. Guidance reaffirms 20% exome/genome revenue growth and ~70% gross margin for the full year. The company's gross margin has been steadily recovering since the 2020 trough. In the latest filing, gross margin stood at 66.7% in Q1 2026, and management reported 70% for Q2. More telling for the payment story, receivables-to-revenue jumped to 75.2%, up 22.4pp YoY, reflecting the unpaid volume the company is deliberately carrying in anticipation of future reimbursement.The Market's Reaction
Shares have already responded: the stock is up 46% over the last 90 days, though it remains 89.8% below its 2021 peak. Investors are clearly beginning to price in the ARR tailwind. Management expects Q3 collection rates to stay flat as workflows are built, with "meaningful improvements in Q4 2026 and the most significant uplift coming in 2027." The company also fortified its balance sheet with a $50M debt facility expansion and a Blackstone Life Sciences equity investment, bringing pro forma liquidity to ~$188M.That single sentence captures the strategic pivot: GeneDx is no longer just selling more tests; it's focused on getting paid for the tests it already runs. If the 70% collection-rate target is even half achieved, the earnings power of this business looks very different. The risk is execution—historical collection rates have been volatile, and payer behavior can shift quickly. But the company is leaning into a highly specific, addressable set of levers, and the early signals—from coverage expansion to reflex product uptake—suggest the thesis is gaining traction.Demand for our services has never been higher. And as we continue to drive adoption of our exome and genome, we must be relentless in our efforts to improve the rate at which we get paid for our services.